Clinical Toxicology Department, Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, 8174673461, Iran.
Clinical Toxicology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.
Sex Med Rev. 2024 Sep 25;12(4):670-680. doi: 10.1093/sxmrev/qeae052.
Methadone maintenance treatment (MMT) is a popular method of treating opioid use disorder. However, the majority of drug-using males experience sexual dysfunction.
This systematic review and meta-analysis examined the possible impact of MMT on sexual dysfunction in drug-using males.
Cochrane, Web of Science, ProQuest, PubMed, and Google Scholar are the international databases that we used in this study. There were neither temporal nor regional limitations on the search. Stata version 14 (StataCorp) was used for data analysis.
When compared with the control group, the MMT group, as measured by the International Index of Erectile Function (IIEF), exhibited significantly greater levels of intercourse satisfaction disorders (standardized mean difference [SMD], -0.52; 95% CI, -0.71 to -0.32), decreased sexual desire/drive (SMD, -0.44; 95% CI, -0.87 to -0.01), lower overall satisfaction (SMD, -0.27; 95% CI, -0.43 to -0.11), and reduced total IIEF score (SMD, -0.69; 95% CI, -0.92 to -0.47). According to the Arizona Sexual Experiences Scale, the MMT group was substantially more satisfied with orgasm than the control group (SMD, 0.58; 95% CI, 0.31-0.86). As determined by the Sexual History Form, MMT was linked to a statistically significant increase in orgasmic dysfunction in comparison with the control group (SMD, 0.65; 95% CI, 0.10-1.20). The Arizona Sexual Experiences Scale revealed a significant decrease in men reporting sexual disorder following MMT as compared with their pretreatment levels.
As compared with control, MMT increased disorders of intercourse satisfaction, sexual desire/drive, and overall satisfaction according to the IIEF. MMT was also associated with a statistically significant decrease in various aspects of male sexual function as compared with pretreatment levels-including erectile function, intercourse satisfaction, orgasmic function, sexual desire/drive, and overall satisfaction. These findings highlight the importance of including sexual dysfunction screening in the routine care of male patients undergoing MMT.
美沙酮维持治疗（MMT）是治疗阿片类药物使用障碍的一种常用方法。然而，大多数吸毒男性都存在性功能障碍。
本系统回顾和荟萃分析旨在探讨 MMT 对吸毒男性性功能障碍的可能影响。
本研究纳入了 Cochrane、Web of Science、ProQuest、PubMed 和 Google Scholar 等国际数据库，检索无时间和地域限制。数据分析采用 Stata 版本 14（StataCorp）。
与对照组相比，MMT 组在国际勃起功能指数（IIEF）评估中，性行为满意度障碍（标准化均数差 [SMD]，-0.52；95%置信区间 [CI]，-0.71 至-0.32）、性欲/驱动力降低（SMD，-0.44；95%CI，-0.87 至-0.01）、总体满意度降低（SMD，-0.27；95%CI，-0.43 至-0.11）和 IIEF 总分降低（SMD，-0.69；95%CI，-0.92 至-0.47）的情况更为显著。根据亚利桑那性体验量表（Arizona Sexual Experiences Scale），MMT 组在性高潮方面的满意度显著高于对照组（SMD，0.58；95%CI，0.31-0.86）。根据性史问卷（Sexual History Form），与对照组相比，MMT 与性高潮功能障碍显著增加相关（SMD，0.65；95%CI，0.10-1.20）。与治疗前相比，MMT 后 Arizona Sexual Experiences Scale 报告性功能障碍的男性比例显著下降。
与对照组相比，MMT 增加了 IIEF 评估中的性行为满意度障碍、性欲/驱动力和总体满意度。与治疗前相比，MMT 还与男性性功能的各个方面显著下降相关，包括勃起功能、性行为满意度、性高潮功能、性欲/驱动力和总体满意度。这些发现强调了在接受 MMT 的男性患者常规护理中纳入性功能障碍筛查的重要性。
